Tanzi AD in a dish mkII, page-16

Now here is another interesting take on the IMAGINE trial and this clever writer posted it before results:

[Although the Reach2HD results were thrilling inasmuch as they offered the possibility that PBT2 might have efficacy, they were distinctly underwhelming compared to the dazzling results seen in mice. The best explanation I have for the discrepancy between the animal and human results in Huntington's disease is that Prana is underdosing patients, possibly by as much as a factor of 10. As a consequence, we are likely to see an ambiguous result from the IMAGINE trial. Existing shareholders will be diluted, as the company needs to raise capital or enter partnerships to fund subsequent trials. My estimate of pre-result risk-adjusted net present value is now reduced from $9.60/share to $4.80-$7.20. ]

The dogs took care of those prices he predicted, but he was pretty much spot on with the rest I think. x10 would take it up to what the mice get per kg. Even so if they used a higher dose and it worked there still would have been questions because IMAGINE was so underpowered.

https://seekingalpha.com/article/2062823-prana-right-drug-wrong-dose